Ateka Zaki, MD
Psychiatry · Richmond, TXNPI 1053321042
Payments from drug & device makers
Across 816 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Bausch Health US, LLC$940
- plus $8K from 26 others
What the payments were for
- Food & beverage$15,04098%
- Education$2892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 94 | $1,888 |
| Vanda Pharmaceuticals Inc. | 59 | $1,330 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $1,284 |
| AbbVie(2 entities) | 82 | $1,253 |
| Alkermes, Inc. | 57 | $1,131 |
| Bausch Health US, LLC | 55 | $940 |
| Teva Pharmaceuticals USA, Inc. | 32 | $781 |
| Corium, LLC | 45 | $747 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $696 |
| Johnson & Johnson | 35 | $645 |
| Axsome Therapeutics, Inc. | 26 | $530 |
| Neos Therapeutics, LP | 34 | $490 |
| Sunovion Pharmaceuticals Inc. | 34 | $486 |
| Lundbeck LLC | 21 | $447 |
| Supernus Pharmaceuticals, Inc. | 20 | $359 |
| Indivior Inc. | 16 | $336 |
| Ironshore Pharmaceuticals Inc. | 19 | $327 |
| Noven Therapeutics, LLC | 16 | $297 |
| Tris Pharma Inc | 13 | $251 |
| E.r. Squibb & Sons, L.L.C. | 10 | $218 |
| Neurocrine Biosciences, Inc. | 8 | $178 |
| Eisai Inc. | 9 | $167 |
| Adlon Therapeutics L.p. | 6 | $109 |
| Merck | 7 | $96 |
| Idorsia Pharmaceuticals US Inc | 5 | $93 |
| Shire North American Group Inc | 4 | $73 |
| Almatica Pharma LLC | 3 | $50 |
| Livanova USA, Inc. | 2 | $40 |
| Bioxcel Therapeutics, Inc. | 2 | $30 |
| Vertical Pharmaceuticals, LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Neuronetics, Inc. | 1 | $15 |
How this compares
$15,329 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $178,964 |
| AuvelityDextromethorphan Hbr/Bupropion | 26 | $32,207 |
| RexultiBrexpiprazole | 23 | $30,585 |
| CaplytaLumateperone Tosylate | 15 | $24,720 |
| VraylarCariprazine Hcl | 14 | $19,819 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $6,230 |
| Modafinil | 19 | $4,754 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 74 | $3,523 |
| Duloxetine Hcl | 53 | $2,368 |
| Aripiprazole | 55 | $1,864 |
| Quetiapine Fumarate | 69 | $1,589 |
| Oxcarbazepine | 14 | $1,513 |
| Olanzapine | 23 | $1,293 |
| LoxapineLoxapine Succinate | 40 | $1,099 |
| Hydroxyzine Hcl | 44 | $1,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $781 | $180,06451 claims |
| Axsome Therapeutics, Inc.Auvelity | $530 | $32,20726 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,888 | $30,58523 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,284 | $24,72015 claims |
| AbbVieVraylar | $1,253 | $19,81914 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $696 | $6,23012 claims |
| Almatica Pharma LLCSertraline Hcl | $50 | $18125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Richmond
- Mustafa ZaidiRichmond$460K
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.